Embrapa has engineered a drought-tolerant soybean using CRISPR technology. Classified by Brazil’s CTNBio as a conventional, non-transgenic product, this innovation aims to reduce crop losses under water-stressed conditions. The variety is currently in the field validation stage, offering a more efficient and cost-effective pathway to commercialization compared to traditional transgenic crops. It represents a significant advancement in precision breeding for sustainable agriculture.
Embrapa has developed a CRISPR-edited soybean variety engineered for improved drought tolerance. By utilizing precise genome editing to modify the plant's endogenous genes, this technology allows the soybean to better withstand water scarcity, thereby reducing potential crop losses during dry periods. Because the process does not involve the introduction of foreign DNA, Brazil's National Technical Commission for Biosafety (CTNBio) has classified this variety as conventional, rather than transgenic. This regulatory status significantly lowers the barrier for development and commercialization compared to traditional GMO approaches.
The technology is at TRL 5. It has demonstrated promising performance in controlled greenhouse environments and has received favorable regulatory classification. It is currently undergoing multi-environment field validation to confirm its agronomic characteristics and commercial viability before potential market deployment. The standard development process from this point typically requires approximately three years of further testing.
Embrapa is Brazil’s national agricultural research enterprise under the Ministry of Agriculture, combining basic and applied R&D with large-scale field operations across dozens of research centers and experimental farms nationwide. Industry engages through regional hubs that co-locate laboratories with test plots and demonstration farms, enabling joint trials, cultivar evaluation, and validation in production environments. Dedicated technology transfer units structure licensing, germplasm access, and sponsored research, while extension interfaces translate results to producers through training and digital advisory tools. Research is supported by Brazilian federal appropriations, complemented by competitive funding from national science and innovation agencies and international partners.